Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $9.49 Analyst target: $37.56 Upside: 295.79%
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.
See the full interactive analysis & chart →Informational only — not investment advice.